Prenetics Q3 Revenue $64.1M Beats Guidance; 2H Adjusted EBITDA Loss Widened to $30-35M
PRE sits 57% above its 52-week low of $11.365.
Summary
Prenetics beat Q3 revenue guidance with $64.1 million, up about 228% year over year, but widened its second-half Adjusted EBITDA loss outlook to $30-35 million from $8-12 million as it pours more into customer acquisition. Cash still grew to $111.5 million, helped by $31.6 million of net fundings from the General Catalyst facility.
Key Events · Earnings and Guidance · PRE
-
Q3 Revenue Beats Guidance at $64.1M
Total revenue of $64.1 million rose about 228% year over year and came in above the $63-64 million guided range; IM8 contributed $62.9 million, above its $61.5-62.5 million range.
-
2H Adjusted EBITDA Loss Widened to $30-35M
Guidance moved from the $8-12 million loss expected in August to $30-35 million, a deliberate increase in customer acquisition spend; at the midpoint that is about 23% of second-half revenue versus about 30% in the first half.
-
General Catalyst Facility Drew $31.6M Net
First quarter of the $1 billion facility: $39.2 million received less $7.6 million remitted, leaving $34.7 million of borrowings on the balance sheet and positive $4.1 million Adjusted Free Cash Flow against $27.5 million of operating cash use.
-
CAC Fell to $285 on Record Spend
Customer Acquisition Cost declined for a second straight quarter, to about $285 from $301, while acquisition marketing reached a record $39.3 million and new customers hit 137,892.
Analysis · PRE · Life Sciences
Revenue is running far ahead of plan — $64.1 million in Q3, up roughly 228% year over year and above the top of the $63-64 million range — but management deliberately doubled down on customer acquisition and now expects a second-half Adjusted EBITDA loss of $30-35 million instead of the $8-12 million guided in August. That is the number that will move the stock: the loss is a choice, funded up to 70% by General Catalyst's $1 billion facility, and the company says it will keep spending as long as cohort returns hold. The offsetting evidence is real — Customer Acquisition Cost fell to about $285 from $301 while spend hit a record $39.3 million, and cash rose to $111.5 million even in a record-spend quarter. The $7.2 million net loss swing is non-cash: a fair-value mark on warrant liabilities that rises when the share price rises, not new dilution or a cash outflow.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, PRE was trading at $17.83 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $276.6M. The 52-week trading range was $11.37 to $27.24. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.